OncoMatch/Clinical Trials/NCT06629597
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Is NCT06629597 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including YL201 and Docetaxel for nasopharyngeal carcinoma.
Treatment: YL201 · Docetaxel · Capecitabine · Gemcitabine — This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CD276 expression testing required (testing required; no eligibility threshold specified)
Subjects are willing to provide the archived or freshly obtained tumor tissue (freshly obtained or archived) for detection of B7-H3 expression
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: PD-(L)1 inhibitor
Have failed prior treatment with PD-(L)1 inhibitors
Must have received: chemotherapy
at least two lines of chemotherapy
Cannot have received: B7-H3-targeted therapy
Previously received B7-H3-targeted drug therapy, including antibody, antibody-drug conjugate (ADC), and chimeric antigen receptor T cell (CAR-T)
Cannot have received: topoisomerase I inhibitor
Prior treatment with a topoisomerase I inhibitor or an antibody-drug conjugate containing a topoisomerase I inhibitor
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06629597 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B7-H3-targeted therapy, topoisomerase I inhibitor disqualifies patients from enrollment.
Does this trial require CD276?
Yes, CD276 expression testing required is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages